Drug Combo Offers Long-Term Glycemic Control in T2DM
Reduction in HbA1c at 104 weeks greater with exenatide plus dapagliflozin versus either drug alone
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Reduction in HbA1c at 104 weeks greater with exenatide plus dapagliflozin versus either drug alone
Only registered members have full access to PracticeUpdate content.